111 related articles for article (PubMed ID: 36372117)
1. Nanostructured lipid carrier-loaded metformin hydrochloride: Design, optimization, characterization, assessment of cytotoxicity and ROS evaluation.
Shete MB; Deshpande AS; Shende PK
Chem Phys Lipids; 2023 Jan; 250():105256. PubMed ID: 36372117
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of in-vitro anti-oral cancer activities of silymarin using dispersion of nanostructured lipid carrier in mucoadhesive in-situ gel.
Shete MB; Deshpande AS; Shende P
Int J Pharm; 2023 Apr; 636():122860. PubMed ID: 36933584
[TBL] [Abstract][Full Text] [Related]
3. Lipid-based nano-formulation platform for eplerenone oral delivery as a potential treatment of chronic central serous chorioretinopathy:
Abd-Elhakeem E; El-Nabarawi M; Shamma R
Drug Deliv; 2021 Dec; 28(1):642-654. PubMed ID: 33787445
[TBL] [Abstract][Full Text] [Related]
4. Targeted Nanostructured Lipid Carrier for Brain Delivery of Artemisinin: Design, Preparation, Characterization, Optimization and Cell Toxicity.
Emami J; Yousefian H; Sadeghi H
J Pharm Pharm Sci; 2018; 21(1s):225s-241s. PubMed ID: 30266137
[TBL] [Abstract][Full Text] [Related]
5. Systematic implementation of quality-by-design (QbD) to develop NSAID-loaded nanostructured lipid carriers for ocular application: preformulation screening studies and statistical hybrid-design for optimization of variables.
Rathod VR; Shah DA; Dave RH
Drug Dev Ind Pharm; 2020 Mar; 46(3):443-455. PubMed ID: 32037896
[TBL] [Abstract][Full Text] [Related]
6. Dermatokinetic assessment of luliconazole-loaded nanostructured lipid carriers (NLCs) for topical delivery: QbD-driven design, optimization, and in vitro and ex vivo evaluations.
Mahmood A; Rapalli VK; Gorantla S; Waghule T; Singhvi G
Drug Deliv Transl Res; 2022 May; 12(5):1118-1135. PubMed ID: 33895936
[TBL] [Abstract][Full Text] [Related]
7. Novel Nanostructured Lipid Carriers Co-Loaded with Mesalamine and Curcumin: Formulation, Optimization and In Vitro Evaluation.
Awasthi A; Kumar B; Gulati M; Vishwas S; Corrie L; Kaur J; Khursheed R; Muhammed RA; Kala D; Porwal O; Babu MR; Chaitanya MVNL; Kumar A; Pandey NK; Dureja H; Chellappan DK; Jha NK; Gupta G; Prasher P; Kumar D; Dua K; Singh SK
Pharm Res; 2022 Nov; 39(11):2817-2829. PubMed ID: 36195824
[TBL] [Abstract][Full Text] [Related]
8. Preparation, characterization, and
Saghafi Z; Mohammadi M; Mahboobian MM; Derakhshandeh K
Drug Dev Ind Pharm; 2021 Mar; 47(3):509-520. PubMed ID: 33650445
[TBL] [Abstract][Full Text] [Related]
9. Effect of the Surfactant and Liquid Lipid Type in the Physico-chemical Characteristics of Beeswax-based Nanostructured Lipid Carrier (NLC) of Metformin.
Qushawy M
Pharm Nanotechnol; 2021; 9(3):200-209. PubMed ID: 33618652
[TBL] [Abstract][Full Text] [Related]
10. Design and evaluation of cabazitaxel loaded NLCs against breast cancer cell lines.
Chand P; Kumar H; Badduri N; Gupta NV; Bettada VG; Madhunapantula SV; Kesharwani SS; Dey S; Jain V
Colloids Surf B Biointerfaces; 2021 Mar; 199():111535. PubMed ID: 33360926
[TBL] [Abstract][Full Text] [Related]
11. Eudragit S-100 Surface Engineered Nanostructured Lipid Carriers for Colon Targeting of 5-Fluorouracil: Optimization and In Vitro and In Vivo Characterization.
Borderwala K; Rathod S; Yadav S; Vyas B; Shah P
AAPS PharmSciTech; 2021 Aug; 22(6):216. PubMed ID: 34386888
[TBL] [Abstract][Full Text] [Related]
12. Co-Delivery of erlotinib and resveratrol via nanostructured lipid Carriers: A synergistically promising approach for cell proliferation prevention and ROS-Mediated apoptosis activation.
Asadollahi L; Mahoutforoush A; Dorreyatim SS; Soltanfam T; Paiva-Santos AC; Peixoto D; Veiga F; Hamishehkar H; Zeinali M; Abbaspour-Ravasjani S
Int J Pharm; 2022 Aug; 624():122027. PubMed ID: 35850183
[TBL] [Abstract][Full Text] [Related]
13. Fabrication of nanostructured lipid carriers ocugel for enhancing Loratadine used in treatment of COVID-19 related symptoms: statistical optimization,
Abdelmonem R; Al-Samadi IEI; El Nashar RM; Jasti BR; El-Nabarawi MA
Drug Deliv; 2022 Dec; 29(1):2868-2882. PubMed ID: 36065090
[TBL] [Abstract][Full Text] [Related]
14. Development of Oral Lipid Based Nano-formulation of Dapagliflozin: Optimization, in vitro Characterization and ex vivo Intestinal Permeation Study.
Zafar A
J Oleo Sci; 2020; 69(11):1389-1401. PubMed ID: 33132278
[TBL] [Abstract][Full Text] [Related]
15. Sucrose ester stabilized solid lipid nanoparticles and nanostructured lipid carriers. I. Effect of formulation variables on the physicochemical properties, drug release and stability of clotrimazole-loaded nanoparticles.
Das S; Ng WK; Tan RB
Nanotechnology; 2014 Mar; 25(10):105101. PubMed ID: 24531790
[TBL] [Abstract][Full Text] [Related]
16. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs?
Das S; Ng WK; Tan RB
Eur J Pharm Sci; 2012 Aug; 47(1):139-51. PubMed ID: 22664358
[TBL] [Abstract][Full Text] [Related]
17. Development and optimization of transferrin-conjugated nanostructured lipid carriers for brain delivery of paclitaxel using Box-Behnken design.
Emami J; Rezazadeh M; Sadeghi H; Khadivar K
Pharm Dev Technol; 2017 May; 22(3):370-382. PubMed ID: 27689412
[TBL] [Abstract][Full Text] [Related]
18. Anti-oxidant Containing Nanostructured Lipid Carriers of Ritonavir: Development, Optimization, and In Vitro and In Vivo Evaluations.
Jitta SR; Bhaskaran NA; Salwa ; Kumar L
AAPS PharmSciTech; 2022 Mar; 23(4):88. PubMed ID: 35296970
[TBL] [Abstract][Full Text] [Related]
19. Formulation of intranasal surface engineered nanostructured lipid carriers of rotigotine: Full factorial design optimization, in vitro characterization, and pharmacokinetic evaluation.
Zafar A; Awad Alsaidan O; Alruwaili NK; Sarim Imam S; Yasir M; Saad Alharbi K; Singh L; Muqtader Ahmed M
Int J Pharm; 2022 Nov; 627():122232. PubMed ID: 36155794
[TBL] [Abstract][Full Text] [Related]
20. Quercetin and piperine enriched nanostructured lipid carriers (NLCs) to improve apoptosis in oral squamous cellular carcinoma (FaDu cells) with improved biodistribution profile.
Chaudhari VS; Gawali B; Saha P; Naidu VGM; Murty US; Banerjee S
Eur J Pharmacol; 2021 Oct; 909():174400. PubMed ID: 34332920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
